Trastuzumab deruxtecan (DAR2)
Trastuzumab deruxtecan (DAR2) (T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 2. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
For research use only. We do not sell to patients.
- CAS No.: 1826843-81-5
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Trastuzumab deruxtecan (DAR2) is a low-drug-to-antibody ratio (DAR) derivative used as a control agent in comparative experiments.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1826843-81-5
-
SMILES
[Trastuzumab deruxtecan (DAR2)]
-
Synonyms
T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645. [Content Brief]
[2]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518. [Content Brief]
[3]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. [Content Brief]
[4]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Trastuzumab deruxtecan (DAR2) Related Classifications
HY-138298B Related Classifications
Powered by Bioz